|
2022-06-07 |
2022-06-06 |
S
Sale
|
Chief Executive Officer
Executive Director
|
60,795
-26.6%
432.88
US$3,915,891
|
60,795
-26.6%
|
432.88
|
US$3,915,891
|
|
|
2022-06-07 |
2022-06-06 |
S
Sale
|
Chief Financial Officer
Officer
|
57,363
+6.4%
365.37
US$4,755,801
|
57,363
+6.4%
|
365.37
|
US$4,755,801
|
|
|
2022-04-01 |
2022-03-31 |
S
Sale
|
VP, Clinical Dev & Med Affairs
Officer
|
70,388
+35.2%
397.09
US$379,738
|
70,388
+35.2%
|
397.09
|
US$379,738
|
|
|
2022-04-01 |
2022-03-31 |
S
Sale
|
Chief Financial Officer
Officer
|
8,116
-5.3%
0.21
US$1,705
|
8,116
-5.3%
|
0.21
|
US$1,705
|
|
|
2022-04-01 |
2022-03-31 |
S
Sale
|
Chief Executive Officer
Executive Director
|
23,633
-4.9%
0.21
US$4,965
|
23,633
-4.9%
|
0.21
|
US$4,965
|
|
|
2021-11-24 |
2021-11-23 |
S
Sale
|
Non-Executive Director
|
10,000
-18.7%
0.60
US$6,018
|
10,000
-18.7%
|
0.60
|
US$6,018
|
|
|
2021-06-07 |
2021-06-04 |
S
Sale
|
See Remarks
Officer
|
1,709
-3.3%
0.81
US$1,376
|
1,709
-3.3%
|
0.81
|
US$1,376
|
|
|
2021-06-07 |
2021-06-04 |
S
Sale
|
VP, Clinical Dev & Med Affairs
Officer
|
1,709
-3.3%
0.81
US$1,376
|
1,709
-3.3%
|
0.81
|
US$1,376
|
|
|
2021-06-07 |
2021-06-04 |
S
Sale
|
Chief Financial Officer
Officer
|
1,709
-1.7%
0.81
US$1,376
|
1,709
-1.7%
|
0.81
|
US$1,376
|
|
|
2019-04-18 |
2019-04-11 |
B
Purchase
|
President & CEO
Executive Director
|
100,000
+55.5%
3.50
US$350,000
|
100,000
+55.5%
|
3.50
|
US$350,000
|
|
|
2018-02-28 |
2018-02-27 |
S
Sale
|
Amzak Capital Management, LLC
Large shareholder
|
5,901
-100.0%
8.26
US$48,760
|
5,901
-100.0%
|
8.26
|
US$48,760
|
|
|
2018-02-28 |
2018-02-27 |
S
Sale
|
Amzak Capital Management, LLC
Large shareholder
|
80,880
-31.6%
8.36
US$675,914
|
80,880
-31.6%
|
8.36
|
US$675,914
|
|
|
2018-02-28 |
2018-02-26 |
S
Sale
|
Amzak Capital Management, LLC
Large shareholder
|
1,500
-0.6%
11.00
US$16,500
|
1,500
-0.6%
|
11.00
|
US$16,500
|
|
|
2017-12-08 |
2017-12-06 |
B
Purchase
|
GREATHOUSE KENNETH
|
55,000
+37.9%
0.61
US$33,407
|
55,000
+37.9%
|
0.61
|
US$33,407
|
|
|
2017-12-04 |
2017-12-01 |
B
Purchase
|
GREATHOUSE KENNETH
|
50,000
+52.6%
0.62
US$31,080
|
50,000
+52.6%
|
0.62
|
US$31,080
|
|
|
2017-12-04 |
2017-11-30 |
B
Purchase
|
GREATHOUSE KENNETH
|
45,000
+90.0%
0.62
US$27,927
|
45,000
+90.0%
|
0.62
|
US$27,927
|
|
|
2017-11-16 |
2017-11-15 |
B
Purchase
|
GREATHOUSE KENNETH
|
15,000
+42.9%
0.58
US$8,674
|
15,000
+42.9%
|
0.58
|
US$8,674
|
|
|
2017-11-16 |
2017-11-14 |
B
Purchase
|
GREATHOUSE KENNETH
|
35,000
+inf%
0.64
US$22,484
|
35,000
+inf%
|
0.64
|
US$22,484
|
|
|
2017-05-25 |
2017-05-25 |
B
Purchase
|
Erbez Georgia
CFO and Chief Business Officer
Officer
|
68,000
+142.4%
1.32
US$89,760
|
68,000
+142.4%
|
1.32
|
US$89,760
|
|
|
2017-05-25 |
2017-05-25 |
B
Purchase
|
WALKER JOHN PETER
Interim CEO
Executive Director
|
37,550
+22.2%
1.37
US$51,338
|
37,550
+22.2%
|
1.37
|
US$51,338
|
|
|
2017-05-25 |
2017-05-24 |
B
Purchase
|
WALKER JOHN PETER
Interim CEO
Executive Director
|
36,166
+27.2%
1.34
US$48,553
|
36,166
+27.2%
|
1.34
|
US$48,553
|
|
|
2017-02-14 |
2017-02-13 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
1,099,996
-53.6%
2.01
US$2,211,432
|
1,099,996
-53.6%
|
2.01
|
US$2,211,432
|
|
|
2017-02-14 |
2017-02-13 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
1,099,996
-53.6%
2.01
US$2,211,432
|
1,099,996
-53.6%
|
2.01
|
US$2,211,432
|
|
|
2016-09-20 |
2016-09-16 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
7,471
-0.4%
0.75
US$5,603
|
7,471
-0.4%
|
0.75
|
US$5,603
|
|
|
2016-09-20 |
2016-09-16 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
7,471
-0.4%
0.75
US$5,603
|
7,471
-0.4%
|
0.75
|
US$5,603
|
|
|
2016-09-15 |
2016-09-13 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
10,000
-0.5%
0.74
US$7,400
|
10,000
-0.5%
|
0.74
|
US$7,400
|
|
|
2016-09-15 |
2016-09-13 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
10,000
-0.5%
0.74
US$7,400
|
10,000
-0.5%
|
0.74
|
US$7,400
|
|
|
2016-08-31 |
2016-08-29 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
50,000
-2.4%
1.01
US$50,440
|
50,000
-2.4%
|
1.01
|
US$50,440
|
|
|
2016-08-31 |
2016-08-29 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
50,000
-2.4%
1.01
US$50,440
|
50,000
-2.4%
|
1.01
|
US$50,440
|
|
|
2016-08-26 |
2016-08-24 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
1,200
-0.1%
1.21
US$1,452
|
1,200
-0.1%
|
1.21
|
US$1,452
|
|
|
2016-08-26 |
2016-08-24 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
1,200
-0.1%
1.21
US$1,452
|
1,200
-0.1%
|
1.21
|
US$1,452
|
|
|
2016-08-22 |
2016-08-19 |
B
Purchase
|
Erbez Georgia
Interim CFO
Officer
|
47,750
+inf%
1.32
US$63,030
|
47,750
+inf%
|
1.32
|
US$63,030
|
|
|
2016-08-22 |
2016-08-19 |
B
Purchase
|
KELLERMAN DONALD J
VP, Clinical Dev & Med Affairs
Officer
|
15,920
+inf%
1.32
US$21,014
|
15,920
+inf%
|
1.32
|
US$21,014
|
|
|
2016-08-22 |
2016-08-19 |
B
Purchase
|
Lewis Hayley
VP, Reg Affairs & Quality
Officer
|
4,775
+inf%
1.32
US$6,303
|
4,775
+inf%
|
1.32
|
US$6,303
|
|
|
2016-08-22 |
2016-08-19 |
B
Purchase
|
WALKER JOHN PETER
Non-Executive Director
|
63,700
+inf%
1.32
US$84,084
|
63,700
+inf%
|
1.32
|
US$84,084
|
|
|
2016-08-22 |
2016-08-19 |
B
Purchase
|
Alataris Konstantinos
President, CEO
Executive Director
|
127,389
+inf%
1.32
US$168,153
|
127,389
+inf%
|
1.32
|
US$168,153
|
|
|
2016-08-22 |
2016-08-19 |
B
Purchase
|
XANTHOPOULOS KLEANTHIS G
Non-Executive Director
|
15,920
+265.3%
1.32
US$21,014
|
15,920
+265.3%
|
1.32
|
US$21,014
|
|
|
2016-07-21 |
2016-07-21 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
8,989
-0.4%
1.33
US$11,957
|
8,989
-0.4%
|
1.33
|
US$11,957
|
|
|
2016-07-21 |
2016-07-21 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
8,989
-0.4%
1.33
US$11,957
|
8,989
-0.4%
|
1.33
|
US$11,957
|
|
|
2016-07-21 |
2016-07-20 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
14,158
-0.7%
1.24
US$17,550
|
14,158
-0.7%
|
1.24
|
US$17,550
|
|
|
2016-07-21 |
2016-07-20 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
14,158
-0.7%
1.24
US$17,550
|
14,158
-0.7%
|
1.24
|
US$17,550
|
|
|
2016-07-21 |
2016-07-19 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
534
-0.0%
1.17
US$625
|
534
-0.0%
|
1.17
|
US$625
|
|
|
2016-07-21 |
2016-07-19 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
534
-0.0%
1.17
US$625
|
534
-0.0%
|
1.17
|
US$625
|
|
|
2016-07-15 |
2016-07-13 |
S
Sale
|
BARRETT M JAMES
Large shareholder
|
13,382
-0.6%
1.20
US$16,060
|
13,382
-0.6%
|
1.20
|
US$16,060
|
|
|
2016-07-15 |
2016-07-13 |
S
Sale
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
13,382
-0.6%
1.20
US$16,060
|
13,382
-0.6%
|
1.20
|
US$16,060
|
|
|
2015-02-02 |
2015-01-30 |
B
Purchase
|
BARRETT M JAMES
Non-Executive Director
Large shareholder
|
23,457
+1.1%
11.00
US$258,027
|
23,457
+1.1%
|
11.00
|
US$258,027
|
|
|
2015-02-02 |
2015-01-30 |
B
Purchase
|
New Enterprise Associates 12, Limited Partnership
Large shareholder
|
23,457
+1.1%
11.00
US$258,027
|
23,457
+1.1%
|
11.00
|
US$258,027
|
|
|
2015-02-02 |
2015-01-30 |
B
Purchase
|
BioMed Realty Trust Inc
Large shareholder
|
26,543
+5.1%
11.00
US$291,973
|
26,543
+5.1%
|
11.00
|
US$291,973
|
|